BridgeMD
The Effect of Cancer Treatments on Speech Perception in Noise, Cognition, and Quality of Life
EU CTIS ID: 2024-513437-21-00
What this study is testing
To assess the short-term effect of different cancer treatments on speech perception in noise.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Age 18-75
- Diagnosis of a cancer that will be treated with a curative intent with either cisplatin, oxaliplatin, cisplatin-based chemoradiation therapy of the head and neck region or radiation therapy of the head and neck region (subjects in the treatment groups)
- Age-normative hearing (according to the ISO standard 7029:2017)
- Ability to provide written informed consent
- Native Finnish speaker
You likely can't join if
- Inability to provide written informed consent
- Current or prior major otological condition that has affected or had the potential to affect hearing
- Conductive hearing loss or asymmetric hearing loss of any severity
- Severe sensorineural hearing loss
- Prior malignancy that has been treated with chemotherapeutics and/or radiation therapy
- Prior use of ototoxic medication
See the full eligibility criteria
- Age 18-75
- Diagnosis of a cancer that will be treated with a curative intent with either cisplatin, oxaliplatin, cisplatin-based chemoradiation therapy of the head and neck region or radiation therapy of the head and neck region (subjects in the treatment groups)
- Age-normative hearing (according to the ISO standard 7029:2017)
- Ability to provide written informed consent
- Native Finnish speaker
- Inability to provide written informed consent
- Current or prior major otological condition that has affected or had the potential to affect hearing
- Conductive hearing loss or asymmetric hearing loss of any severity
- Severe sensorineural hearing loss
- Prior malignancy that has been treated with chemotherapeutics and/or radiation therapy
- Prior use of ototoxic medication
- Any condition that, in the opinion of the investigator, would interfere with adherence to study requirements
- Pregnancy, breast-feeding, or aim of becoming pregnant during the study
- Allergy or hypersensitivity to study medications or their ingredients
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.